الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 213 |  |  |
| | | from | 213 | | |
Abstract
HCV infection is one of the main causes of chronic liver
disease worldwide .
The long-term impact of HCV infection is highly variable,
ranging from minimal histological changes to extensive fibrosis and
cirrhosis.
Liver cirrhosis follows an indolent course and eventually
patients’ disease condition progress without any gross manifestation
to the complications of liver decompensation such as variceal
bleeding from portal hypertension, ascites , spontaneous bacterial
peritonitis, hepatorenal syndrome, hepatic encephalopathy and
cardiopulmonary complications like porto-pulmonary hypertension
and hepato-pulmonary syndrome that responsible for significant
morbidity and mortality in patients with liver cirrhosis and accounts
for most indications of liver transplantation .
Direct-acting antiviral agents (DAAs) have revolutionized the
treatment of hepatitis C virus (HCV) infection over the last 5 years.
As a result of better understanding of the HCV life cycle, specific
DAAs have been developed for HCV that are able to target the viral
proteins implicated in replication of the virus. Treatment of hepatitis
C is now extremely effective, tolerable and requires a short duration
of intake of oral agents.
Sustained virologic response to interferon-free therapies with
various combinations of direct -acting antivirals ameliorates HCVinduced
portal hypertension , significantly reduces fibrosis